No Data
No Data
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
Needham analyst Joseph Stringer maintains $Stoke Therapeutics(STOK.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 39.9% and
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Stoke Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 65.29% Needham $22 → $22 Reiterates Buy → Buy 05/07/2024 162.96% HC Wainwright & Co. $35 → $35
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to
Stoke Therapeutics Announces Chief Operating Officer Huw Nash To Step Down, Will Continue As Chief Business Officer Effective June 18, 2024
Stoke Therapeutics Announces Chief Operating Officer Huw Nash To Step Down, Will Continue As Chief Business Officer Effective June 18, 2024